科研之友
微信
新浪微博
Facebook
分享链接
摘要
Icariin (Ic) has been demonstrated as a potent osteoinductive compound for bone tissue engineering. However, toxic side effects of the drug and poor biocompatibility of drug delivery systems (DDSs) still limit its application for bone repair in the clinic. To overcome these disadvantages and utilize the osteoinductivity of Ic, we developed a novel method to utilize Ic as an Ic-derived osteoinductive extracellular matrix (ECM) on small intestinal submucosa (SIS) (Ic-ECM-SIS). The generated Ic-ECM-SIS scaffolds, as a natural construct, exhibited much better biocompatibility (including cell adhesion, cell survival and cell proliferation) than Ic-SIS scaffolds generated by traditional DDSs. Meanwhile, osteogenic differentiation was promoted by Ic-ECM-SIS with higher expression of alkaline phosphatase, bone sialoprotein and osteocalcin than ECM-SIS, which was same as Ic-SIS. BMP-4 expression was further increased in the cells on Ic-ECM-SIS compared to that on Ic-SIS. A mouse calvarial defect model was introduced to evaluate the function of Ic-ECM-SIS on bone regeneration in vivo. The bone regeneration was enhanced in the defects implanted with Ic-ECM-SIS, with a higher new bone formation ratio (BV/TV) than the defects implanted with ECM-SIS or Ic-SIS. Angiogenesis was also promoted by Ic-ECM-SIS implantation when compared with ECM-SIS or Ic-SIS. Thus, this work proposes a novel method for applying a drug as a drug-derived ECM-modified scaffold for bone tissue engineering.
